STAT3 and chronic myelogenous leukemia, BCR-ABL1 positive: We have already reported activation of STAT3 at tyrosine 705 (pSTAT3Y705) in TKI resistance, and that dual targeting of STAT3 and BCR-ABL1 induced synthetic lethality in TKI-resistant CML [19, 20].